Bârzu T, Pascal M, Maman M, Roque C, Lafont F, Rousselet A
Sanofi Recherche, Gentilly, France.
J Cell Physiol. 1996 Apr;167(1):8-21. doi: 10.1002/(SICI)1097-4652(199604)167:1<8::AID-JCP2>3.0.CO;2-T.
We studied the binding and entry of fluorescein (FITC)-labeled heparin derivatives into rat aortic smooth muscle cells (SMC) by confocal microscopy. FITC-labeled heparin fractions or FITC-labeled SR 80037A, a potent antiproliferative heparin derivative (Bârzu et al., Eur. J. Pharmacol., 219:225-233 1992), were prepared and their antiproliferative activity was confirmed. By incubating SMC with FITC-labeled heparins, a specific cell-associated fluorescence was found. Cellular fluorescence was mostly located around the nucleus and at the level of cell contacts or cell adhesion. The fluorescence was displaced neither by chasing with excess of unlabeled heparins nor by washing with 1 M NaCl, which proved that labeled heparins had been internalized by SMC. Kinetics of internalization of FITC-heparins suggested receptor-mediated endocytosis of heparins by SMC. Double labeling of SMC with biotinylated Concanavalin A and FITC-SR 80037A also indicated that heparin derivative enters the endocytic pathway. The process was accelerated when serum was present in the incubation medium. Treatment of cells with chloroquine (50 microM) induced accumulation of FITC-SR 80037A in the late endosomes, around the nucleus. No fluorescence labeling could be evidenced inside the nucleus. Neither electron microscopy nor cell fractionation experiments performed with SMC previously incubated with [3H]-heparin were able to ascertain nuclear uptake of heparin, as proposed by other workers (Busch et al., Cell Biol., 116:31-42; 1992; Sing et al., Drug Dev. Res., 29:129-136 1993). The cell-associated fluorescence was very weak in SMC resistant to the antiproliferative activity of heparin, selected by long-term heparin treatment (HT-SMC) as previously shown [Bârzu et al., J. Cell. Physiol., 160:239-248, 1994]. The HT-SMC differed from control SMC with regard to expression of extracellular matrix proteins. These cells exhibited very low expression of fibronectin and prevalent expression of laminin and synthesized less cell-associated glycosaminoglycans. From our results, the following conclusions can be drawn: (1) the antiproliferative heparins are bound and internalized by SMC without being taken up into the nucleus; (2) there is a correlation between the binding and/or the internalization process and the sensitivity of SMC to the antiproliferative activity of heparins; and (3) selection of heparin-resistant SMC by long treatment with heparin results in particular growth pattern of SMC (absence of focal overgrowth), associated with changes in the expression of the extracellular matrix components (fibronectin, laminin, and cell-bound glycosaminoglycans).
我们通过共聚焦显微镜研究了异硫氰酸荧光素(FITC)标记的肝素衍生物与大鼠主动脉平滑肌细胞(SMC)的结合及进入情况。制备了FITC标记的肝素组分或FITC标记的SR 80037A(一种有效的抗增殖肝素衍生物,Bârzu等人,《欧洲药理学杂志》,219:225 - 233,1992年),并证实了它们的抗增殖活性。通过将SMC与FITC标记的肝素孵育,发现了一种与细胞相关的特异性荧光。细胞荧光大多位于细胞核周围以及细胞接触或细胞黏附水平处。用过量未标记的肝素追赶或用1 M NaCl洗涤都不能使荧光消失,这证明标记的肝素已被SMC内化。FITC - 肝素内化动力学表明SMC通过受体介导的内吞作用摄取肝素。用生物素化的伴刀豆球蛋白A和FITC - SR 80037A对SMC进行双重标记也表明肝素衍生物进入了内吞途径。当孵育培养基中存在血清时,该过程会加速。用氯喹(50 microM)处理细胞会导致FITC - SR 80037A在细胞核周围的晚期内体中积累。在细胞核内未发现荧光标记。如其他研究者所提出的(Busch等人,《细胞生物学》,116:31 - 42;1992年;Sing等人,《药物研发研究》,29:129 - 136,1993年),用[3H] - 肝素预先孵育SMC后进行的电子显微镜检查和细胞分级分离实验均未能确定肝素是否被细胞核摄取。如先前所示[Bârzu等人,《细胞生理学杂志》,160:239 - 248,1994年],通过长期肝素处理(HT - SMC)选择的对肝素抗增殖活性具有抗性的SMC中,与细胞相关的荧光非常弱。HT - SMC在细胞外基质蛋白表达方面与对照SMC不同。这些细胞纤连蛋白表达极低,层粘连蛋白表达普遍,且合成的细胞相关糖胺聚糖较少。从我们的结果可以得出以下结论:(1)抗增殖肝素被SMC结合并内化,但未被细胞核摄取;(2)结合和/或内化过程与SMC对肝素抗增殖活性的敏感性之间存在相关性;(3)通过长期用肝素处理选择肝素抗性SMC会导致SMC出现特定的生长模式(无局灶性过度生长),这与细胞外基质成分(纤连蛋白、层粘连蛋白和细胞结合糖胺聚糖)表达的变化有关。